Related references
Note: Only part of the references are listed.An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: The European School for Advanced Studies in Ophthalmology classification
Giacomo Panozzo et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2020)
Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study)
Rita Ehrlich et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2019)
ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA An Independent Analysis of Protocol i Study Data
Pravin U. Dugel et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2019)
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity A Randomized Clinical Trial
Carl W. Baker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study
Catharina Busch et al.
ACTA DIABETOLOGICA (2019)
Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis
Amy S. Babiuch et al.
INTERNATIONAL JOURNAL OF RETINA AND VITREOUS (2019)
Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success
Rita Laiginhas et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2018)
Clinical pharmacology of intravitreal anti-VEGF drugs
Stefano Fogli et al.
EYE (2018)
Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
Ali Demircan et al.
JOURNAL OF OPHTHALMOLOGY (2018)
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment A Secondary Analysis of a Randomized Clinical Trial
Neil M. Bressler et al.
JAMA OPHTHALMOLOGY (2018)
Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T
Neil M. Bressler et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2018)
Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
Clare F. McCloskey et al.
OPHTHALMOLOGY AND THERAPY (2018)
Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies
Paul Mitchell et al.
OPHTHALMOLOGY RETINA (2018)
A Prospective Randomized Comparative Dosing Trial of Ranibizumab in Bevacizumab-Resistant Diabetic Macular Edema The REACT Study
Justis P. Ehlers et al.
OPHTHALMOLOGY RETINA (2018)
The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema
Catherine Egan et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2017)
Ranibizumab for persistent diabetic macular edema after bevacizumab treatment
Gabriel Katz et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2017)
Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema
V. E. Konidaris et al.
EYE (2017)
Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema
Bobak Bahrami et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)
Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
Filipe Mira et al.
JOURNAL OF OPHTHALMOLOGY (2017)
Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
Antoine Herbaut et al.
JOURNAL OF OPHTHALMOLOGY (2017)
Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials
Marco A. Zarbin et al.
JAMA OPHTHALMOLOGY (2017)
Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab
Mohammed Ashraf et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2017)
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR. net Protocol T
Sophie Cai et al.
CURRENT OPINION IN OPHTHALMOLOGY (2017)
Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1)
Kevin J. Blinder et al.
CLINICAL OPHTHALMOLOGY (2017)
Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema
Ehsan Rahimy et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2016)
Early and Long-Term Responses to Anti Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data
Victor H. Gonzalez et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2016)
Short-Term Outcomes of Switching to Ranibizumab Therapy for Diabetic Macular Edema in Patients with Persistent Fluid After Bevacizumab Therapy
Jae Hyung Lee et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2016)
RANIBIZUMAB FOR DIABETIC MACULAR EDEMA REFRACTORY TO MULTIPLE PRIOR TREATMENTS
Thomas A. Ciulla et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment
Susan B. Bressler et al.
JAMA OPHTHALMOLOGY (2016)
Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial
Chelsea Fechter et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2016)
Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness
Chirag P. Shah et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2016)
Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study)
D. S. Dhoot et al.
EYE (2015)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
John A. Wells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab
Edward H. Wood et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2015)
Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema
Joel Hanhart et al.
CASE REPORTS IN OPHTHALMOLOGY (2015)
Global estimates of diabetes prevalence for 2013 and projections for 2035
L. Guariguata et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials RISE and RIDE
David M. Brown et al.
OPHTHALMOLOGY (2013)
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos et al.
ANGIOGENESIS (2012)
Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab
Maria Salling Eghoj et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?
Susanne Binder
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
Comparing protein VEGF inhibitors: In vitro biological studies
Lanlan Yu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Michael J. Elman et al.
OPHTHALMOLOGY (2010)
Share Paper
